Summary
Becton Dickinson & Co. (BDX) reported its first quarter fiscal year 2014 results, ending December 31, 2013. The company demonstrated solid revenue growth, with total revenues reaching $2.015 billion, a 6.0% increase compared to the prior year. This growth was driven by volume increases across all three business segments: Medical, Diagnostics, and Biosciences, with particular strength noted in the Medical and Biosciences segments. The company continued to focus on returning value to shareholders, repurchasing $189 million of its common stock and paying $106 million in dividends during the quarter. Despite overall revenue growth, operating income faced some pressure due to factors such as unfavorable foreign currency translation, higher start-up costs, amortization of intangible assets, and increased raw material costs. A significant factor impacting profitability was the U.S. medical device excise tax, which contributed $14 million or $0.05 per diluted share. The company's financial position remains strong, with $2.5 billion in cash and short-term investments as of December 31, 2013, and a robust operating cash flow of $355 million for the quarter. Management remains focused on strategic investments in research and development and geographic expansion to drive future growth.
Financial Highlights
48 data points| Revenue | $2.02B |
| Cost of Revenue | $980.00M |
| Gross Profit | $1.03B |
| R&D Expenses | $126.00M |
| SG&A Expenses | $531.00M |
| Operating Expenses | $1.64B |
| Operating Income | $378.00M |
| Interest Expense | $34.00M |
| Net Income | $271.00M |
| EPS (Basic) | $1.40 |
| EPS (Diluted) | $1.37 |
| Shares Outstanding (Basic) | 194.20M |
| Shares Outstanding (Diluted) | 198.11M |
Key Highlights
- 1Total revenues for the quarter increased by 6.0% year-over-year to $2.015 billion, driven by volume growth across all segments.
- 2The Medical segment saw an 8.2% revenue increase, bolstered by strong international sales and the contribution of acquired Safety Syringes, Inc.
- 3Operating income was impacted by foreign currency headwinds, increased costs (raw materials, start-up, intangible amortization), and the U.S. medical device excise tax.
- 4The company returned $295 million to shareholders through share repurchases ($189 million) and dividends ($106 million) in the quarter.
- 5Net cash provided by continuing operating activities significantly increased to $355 million from $226 million in the prior year's comparable period.
- 6BD ended the quarter with a strong liquidity position, holding $2.5 billion in cash and short-term investments.
- 7The company is actively managing legal proceedings, including an antitrust class action settlement for $22 million, while asserting defenses in other ongoing litigations.